logo
Plus   Neg
Share
Email

Biogen To Acquire Clinical Stage PF-05251749 From Pfizer - Quick Facts

Biogen Inc. (BIIB) announced an agreement to acquire from Pfizer Inc. (PFE) PF-05251749, a CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases. The deal will include an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.

PF-05251749 has previously demonstrated an acceptable safety profile and proof of mechanism in a phase 1a clinical study. Biogen plans to develop this asset for the treatment of Sundowning in Alzheimer's disease and Irregular Sleep Wake Rhythm Disorder in Parkinson's disease. The company aims to initiate a phase 1b study in the fourth quarter of 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Casino operator MGM Resorts International said it was the victim of a data breach in 2019 after a report claimed that the details of more than 10.6 million hotel guests were exposed. Technology website ZDNet reported about the incident late on Wednesday, saying that the personal details of more than 10.6 guests who stayed at MGM Resorts hotels were published on a hacking forum this week. Amid the ongoing troubles with its 737 MAX commercial planes grounding since March 2019, Boeing (BA) has secured a five-year U.S. Air Force contract to sustain and modernize the Global Decision Support System, or GDSS. The financial terms of the deal were not disclosed. The contract was awarded to Tapestry Solutions, part of Boeing Global Services. Reinsurer Swiss Re reported Thursday significantly higher profit in fiscal 2019 driven by higher premiums mainly in property and casualty businesses, despite heavy natural catastrophe losses. The company also said it will propose higher dividend and share buyback of up to 1 billion Swiss Francs. Swiss Re were losing around 4 percent in trading.
Follow RTT
>